Hypertensive patients are at particular risk of cardiovascular complications, possibly related to endothelial damage or dysfunction, or to abnormal angiogenesis. These pathophysiologic processes are assessable by measurement of plasma levels of von Willebrand factor (vWf), and by vascular endothelial growth factor (VEGF) and its soluble receptor (sFlt-1). We hypothesized that these markers would correlate with the Framingham cardiovascular risk score and would be responsive to treatment. Methods: We measured these markers by enzymelinked immunosorbent assay in 286 patients with hypertension (239 men; mean age 63 years; mean systolic blood pressure [BP]/diastolic BP 162/89 mm Hg) and additional risk factors, and related them to the patient's cardiovascular disease (CVD) and cerebrovascular accident (CVA) risk, using the Framingham equation. Patients were compared with 60 healthy normotensive controls. In 248 patients, the effects of 6 months of intensified cardiovascular risk factor management, including BP and (where appropriate) lipid-lowering treatment, were investigated.
I
n healthy subjects, normal endothelial function and integrity play an important role in minimizing the risk of thromboembolic events by providing an anticoagulant environment and by maintaining vascular tone. Loss of endothelial integrity is present in atherosclerosis and its risk factors, including hypertension, and may be a causal link between each particular risk factor, the development of atherosclerosis, and clinical events, such as myocardial infarction and stroke. 1, 2 Patients with hypertension exhibit loss of endothelial cell integrity by demonstrating impaired flow-mediated dilatation and increased levels of plasma markers such as von Willebrand factor (vWf) and soluble E selectin. 3, 4 Furthermore, epidemiologic studies indicate that increased levels of these plasma markers bring with them an increased risk of a poor prognosis. 1 Data demonstrating increased vascular resistance in essential hypertension points to vascular mechanisms as possible underlying causes for high blood pressure (BP). 5 One concept of impaired vascular development is based on structural alterations of microvascular beds such as capillary rarefaction. 6, 7 Because angiogenic growth factors are major regulators of blood vessel formation, abnormal angiogenesis may affect these markers. Evidence of angiogenesis in full-blown atherosclerosis includes increased numbers of vasa vasorum in arteries burdened with atheroma 8 with increased expression of angiogenic growth factors. 9 We have recently reported pilot data of increased plasma levels of one such growth factor, vascular endothelial growth factor (VEGF), in hypertensive patients, suggesting that the impaired capacity for vascular growth is related to abnormal regulation of VEGF. 10 Many individual factors have been identified as likely contributors to the overall risk of developing a cardiovascular event. As a result, in the Framingham study, a mathematical equation has been developed to estimate future cardiovascular disease (CVD) and cerebrovascular accident (CVA) risk, taking into account the established risk factors such gender, age, smoking, total and HDL cholesterol, diabetes mellitus, and BP. 11 Recently, hemostatic markers (such as fibrinogen and vWf) have also been associated with increased risk of cardiovascular events, 1, 12, 13 although these factors have yet to be factored into a cardiovascular risk equation.
The objective of the present study was to test the hypothesis that there would be a relationship between endothelial damage (as assessed by vWF), angiogenesis (associated with plasma levels of VEGF and its soluble receptor [sFlt-1]), and the degree of CVD and CVA risk (as assessed by the Framingham equation) in subjects whose primary cardiovascular risk factor was hypertension. We also tested the hypothesis that the effects of 6 months of intensified cardiovascular risk factor management, including BP and (where applicable) hypercholesterolemia treatment, on these indices would be beneficial. Such data may be useful in developing extended models or adaptations of the Framingham equation.
Methods

Subjects
Patients were recruited from among those screened as part of the Anglo-Scandinavian Cardiac Outcome Trial (AS-COT) at our dedicated research clinic at the City Hospital, Birmingham, UK. The methods for the ASCOT study have previously been described, 14, 15 and the present analysis describes the substudy related to vWF, VEGF, and its soluble receptor sFt-1.
In brief, the inclusion criteria for ASCOT were patients aged between 40 and 80 years with either newly diagnosed untreated hypertension with systolic BP Ͼ160 mm Hg or diastolic BP Ͼ100 mm Hg or treated hypertension with systolic BP Ͼ140 mm Hg or diastolic BP Ͼ90 mm Hg. The BP was measured after 10 min of rest in a quiet room with an Omron HEM 705-CP (Hoofddorp, The Netherlands); the latter device fulfills the criteria of the British Hypertension Society (BHS) and American Association for the Advancement of Medical Instrumentation (AAMI) protocols. 16 Three consecutive BP readings were taken and the average of the last two readings was used. We excluded patients with secondary hypertension or malignant hypertension, ongoing angina, as well as those with renal or hepatic impairment, infection or inflammatory disorders, malignancy and concurrent therapy with warfarin.
The hypertensive patients were assessed for their future cardiovascular risk requiring three or more risk factors to be included into ASCOT. Risk factors included: 1) left ventricular hypertrophy according to Cornell voltage duration product (Ͼ2440 mv.ms) or Sokolow Lyon criteria (Ͼ38 mV); 2) other electrocardiographic abnormalities (left ventricular strain pattern, abnormal Q waves, left bundle branch block, ST-T changes compatible with ischemic heart disease); 3) history of diabetes mellitus according to World Health Organization criteria; 4) medical history of cerebrovascular event, including transient ischemic attack; 5) male sex; 6) age Ͼ 55 years; 7) microalbuminuria/proteinuria; 8) smoking; 9) plasma total cholesterol/HDL cholesterol; 10) family history of first degree relative before the age of 55 years (men) or 60 years (women); and 11) peripheral vascular disease according to Edinburgh claudication questionnaire. 17 The 10-year CVD and CVA risk scores were calculated using the Framingham equation.
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Hypertensive patients with less than three risk factors (low risk, n ϭ 38; 26 men, mean age 59 years (SD 8.5 years) were not entered into ASCOT and only the 248 high risk subjects (213 men; mean age 64 years (SD 7.9 years) were entered into the trial. Thus, the impact of cardiovascular risk factor management, with BP and hypercholesterolemia treatment as appropriate, was determined in these 248 patients. This was a "package of care" that included health education (smoking cessation, regular exercise, reduction in weight and salt intake), antihypertensive therapy (with either amlodipine Ϯ perindopril or atenolol Ϯ bendroflumethiazide), and if total cholesterol was Յ6.5 mmol/L (250 mg/mL), patients were randomized into the lipid arm in a double-blind manner to receive atorvastatin (10 mg) or placebo. Patients with total cholesterol Ͼ6.5 mmol/L (250 mg/mL) were referred back to their physician for management of their hypercholesterolemia. The antihypertensive treatment was adjusted accordingly by us to aim for target BP for nondiabetic patients of Ͻ140 mm Hg systolic and Ͻ90 mm Hg diastolic. In patients with diabetes mellitus, the goal was Ͻ130 mm Hg systolic and Ͻ80 mm Hg diastolic. At the 6-month visit, further blood samples were taken for measurement of lipids, vWF, VEGF, and sFlt-1 levels.
We also studied a healthy control group that consisted of 60 healthy normotensive controls (48 men; mean age 61 years, SD 7.0 years) recruited from healthy hospital staff, relatives of the patients, and those hospitalized for routine cataract surgery. The subjects had no clinical evidence of vascular, metabolic, neoplastic, or inflammatory disease, by careful history, examination, and routine laboratory tests. These subjects were normotensive and in sinus rhythm, and were not taking aspirin, warfarin, lipid-lowering, antihypertensive, or nonsteroidal anti-inflammatory drugs, or antibiotics.
Laboratory Methods
Blood was drawn after an 8-h fasting period with minimal trauma from the antecubital vein. Samples were put on ice for 5 min and then centrifuged at 2000 rpm for 20 min. The plasma and serum was stored at Ϫ70°C until assayed. In the routine hospital pathology laboratory, serum was analyzed by standard techniques for total cholesterol, triglycerides, and HDL cholesterol. Levels VEGF and sFlt-1 in citrated plasma were measured by enzyme-linked immunosorbent assay (ELISA) using commercially available reagents and recombinant standards (R&D Systems, Abingdon, UK). 18 The VEGF assay has a minimum sensitivity of 0.5 pg/mL with an intra-assay coefficient of 4.4% and interassay coefficient of 9.1%. The sFlt-1 assay has a minimum sensitivity of 50 ng/mL with an intra-assay coefficient of 3.7% and interassay coefficient of 8.8%. Levels of vWF were analyzed with a sandwich ELISA using commercially available reagents and standards (Dako Ltd., Ely, Cambs, UK). 19 The assay has a minimum sensitivity of 0.5 IU/dL with an intra-assay coefficient of Ͻ5% and interassay coefficient of Ͻ10%. All laboratory work was performed in blinded fashion with respect to the identity of the samples.
Power Calculations and Statistical Analysis
We hypothesized a correlation between the three plasma markers and the Framingham risk scores with at least a value of r ϭ 0.20 at a two-sided significance level of P ϭ .02 and a power of 0.85. The minimum number of data points to achieve this is 278, which we have slightly exceeded. The inclusion of 60 controls is not primarily to provide a case-control comparison but simply to illustrate levels of the various measures in a local healthy population. Nevertheless, these numbers provide a power of at least 0.80 at P Ͻ .05 to define a difference of one-third of a standard deviation in a normally distributed index such as vWf. Intervening with therapy in 248 subjects provides sufficient power (minimum 1 Ϫ ␤ ϭ 0.80) to detect a significant two-sided difference at P Ͻ .05 or a one-sided difference of P Ͻ .025 of one-quarter of a standard deviation in a normally distributed index such as vWf. 20, 21 Continuous data were subjected to the Ryan-Joiner test to assess distribution. Those normally distributed are expressed as mean and SD, whereas those not normally distributed are shown as median and interquartile range (IQR). Correlation between cardiovascular risk scores and the measured parameters were assessed according to Spearman's method. Data between cases and controls were analyzed using Student t test or the Mann-Whitney U test, whereas paired comparisons were made using the paired t test or paired Wilcoxon's test, as appropriate.
Stepwise multiple regression analyses were used with VEGF, sFlt-1, and vWF as dependent variables and clinical indices (age, sex, BP, medical history, treated/untreated status at baseline, etc.) as predictors. All statistical calculations were performed on a microcomputer using a commercially available statistical package (SPSS 10.0 for Windows, Chicago, IL). A P value Ͻ .05 was considered statistically significant.
Results
Baseline Values
Plasma VEGF and vWf levels were higher, but sFlt-1 levels were lower, in the hypertensives, compared to controls. As expected, the hypertensive patients also had a worse overall risk factor profile than the controls. Apart from differences in BP, there were no significant differences in the measured indices between hypertensive patients who were not taking antihypertensive therapy at baseline, compared to those on such therapy (Tables 1 and 2) .
When high risk subjects (Ն3 risk factors) were compared to low risk subjects (with Ͻ3 risk factors, n ϭ 38), the high risk group were older, more likely to be male and white. Medical history was similar in the two groups, although mean BP was not significantly different. Median VEGF and mean vWf levels were higher, whereas sFlt-1 levels lower, in the high risk group compared to low risk hypertensives (Table 3) . Similar trends for the research indices were noted when patients in the highest (Q4) and lowest (Q1) quartiles of CVD and CVA risk scores were compared (Tables 4 and 5) .
When whites were compared with non-whites, the Indo-Asian patients were younger and had a lower mean 10-year CVD risk score, whereas Afro-Caribbean patients had lower mean cholesterol levels, as well as a higher prevalence of electrocardiographic left ventricular hypertrophy and diabetes (Table 6 ). There were no differences between whites and non-whites with regard to mean BP and VEGF, sFlt-1 and vWf levels, at baseline.
Effects of Intensive Cardiovascular Risk Factor Management
Plasma levels of vWf and VEGF decreased, whereas sFlt-1 increased, after 6 months of treatment ( Table 7) . As expected, BP decreased in all patients. Total cholesterol also decreased, to be partially expected as an unknown proportion of the patients were being treated with atorvastatin as part of the placebo-controlled lipid arm in the ASCOT study. There was no significant correlation be-tween changes in BP and corresponding changes in VEGF, sFlt-1, or vWF levels (data not shown).
Correlations and Multivariate Analysis
When the measured indices were correlated with clinical risk factors, there was a significant correlation between VEGF levels and age (Spearman, r ϭ 0.153, P ϭ .004), systolic (r ϭ 0.283, P Ͻ .001) and diastolic BP (r ϭ 0.159, P ϭ .003). Similar correlations were observed for vWf (age: r ϭ 0.264, P Ͻ .001; systolic BP: r ϭ 0.308, P Ͻ .001; diastolic BP: r ϭ 0.113, P ϭ .039). There were no significant correlations between vWf, VEGF, or sFlt-1, and the other established risk factors for cardiovascular disease assessed in this study (gender, total cholesterol, or (29) .787
Abbreviations as in Table 1 . Analysis based on high risk cohort (n ϭ 248) only.
HDL cholesterol) (data not shown).
Stepwise multiple regression analysis for the three markers demonstrated that only age, treatment status (treated/untreated), and medical history of cerebrovascular disease were independent predictors for baseline vWf levels (P Ͻ .05) but not for VEGF or sFlt-1. Plasma VEGF and vWf levels were significantly positively correlated with 10-year CVD and CVA risk scores, according to the Framingham equation (P Ͻ .01) ( Table  8 ), whereas sFlt-1 was negatively correlated with these risk scores (P Ͻ .01) (Figs. 1-3) .
Plasma levels of VEGF correlated with vWf (r ϭ 0.307, P Ͻ .001) as well as with sFlt-1 (r ϭ 0.254, P ϭ .001). There was also a negative correlation between vWf and sFlt-1 levels (r ϭ Ϫ0.056, P ϭ .328) ( Table 8) . Abbreviations as in Tables 1-3 .
Discussion
The present study confirms previous observations in much smaller studies of increased plasma vWf and VEGF, and lowered sFlt-1 levels, in hypertension and vascular disease. 4, 10 In addition, we have demonstrated that in this large cohort of patients, these indices are particularly abnormal in high risk hypertensives (with three or more clinical risk factors, compared to a low risk group), or the highest quartile of CVD or CVA risk scores according to the Framingham equation, and can also be correlated to these CVD and CVA risk scores. Furthermore, after 6 months of intensive cardiovascular risk factor management (including antihypertensive/hypercholesterolemia treatment), both VEGF and vWF were reduced; in addi- tion, sFlt-1 levels decreased with increased cardiovascular risk and were increased after pharmacologic management. These data suggest abnormal angiogenesis, as well as endothelial damage in hypertension which, can be beneficially improved with pharmacologic treatment and cardiovascular risk factor management. Increased plasma levels of vWf support the hypothesis of endothelial cell damage or dysfunction in hypertension. [1] [2] [3] [4] Abnormal endothelial function has also been demonstrated by means of flow-mediated dilatation, 22, 23 but 
FIG. 2. A)
Correlation between VEGF levels and CVD risk. B) Correlation between VEGF levels and CVA risk. VEGF ϭ vascular endothelial growth factor; other abbreviations as in Fig. 1 .
this method is too inconvenient to apply to large epidemiologic studies, requiring specialized equipment and technical expertise. A more convenient marker for the assessment of endothelial damage/dysfunction is vWf, which is measured easily by ELISA and high levels carry a poor prognosis. 12, 13 Importantly, therefore, in our study, vWf correlates with a mathematically derived index of the risk of future cardiovascular and cerebrovascular events. 11, 24 In the Hoorn study, the highest tertile of vWF had a threefold increased incidence of cardiovascular mortality after adjustment for age, sex, and glucose tolerance; this difference persisted after adjustments for multiple other risk factors and held true in both diabetic and nondiabetic subjects. 25 Furthermore, elevated vWF was significantly associated with all-cause mortality. 25 Patients with acute stroke have increased levels of plasma vWF and highest levels indicate a worse prognosis, at 1 and 6 months after a stroke. 26 Interestingly, VEGF correlates significantly, along with a negative correlation for sFlt-1 levels, with the overall CVD and CVA risk when assessed according to the Framingham equation. The latter integrates the risk factors of age, gender, systolic/diastolic BP, smoking status, history of diabetes mellitus, presence of left ventricular hypertrophy, and total and HDL cholesterol. 24 This validated method for assessing cardiovascular and stroke risk based on individual risk factors is now widely used for risk stratification to target the appropriate patients for lipidlowering therapy or the initiation of antihypertensive treatment in persons having high-to-normal and mild degrees of hypertension. 27 Our observations that vWf and VEGF positively correlate with the Framingham risk scores, and sFlt-1 inversely, might assist as alternative indices to assess the future cardiovascular and cerebrovascular risk in hypertensive patients. These markers also correlate with some of the individual risk factors for cardiovascular disease (age, systolic and diastolic BP), but interestingly, there was no significant correlation with total cholesterol, HDL cholesterol, or gender. Perhaps vWf and VEGF might assess other risk factors not included in the equation as it stands, but may provide additional information needed to refine overall cardiovascular risk. Indeed, the relation of these measured indices to the 10-year CVD and CVA risk scores suggests some additional measure of general risk stratification that might potentially be useful in identifying high risk individuals at a very early stage for close monitoring and possible early antihypertensive intervention.
In the present study, abnormal levels of vWf, sFlt-1, and VEGF suggest that these molecules may also be involved in the pathogenesis of hypertension in view of their associations with abnormal endothelial function and angiogenesis. Abnormal angiogenesis has been demonstrated in hypertensive animal models as well as in different stages of hypertension in humans. 6, 7, 10, 28 There seems to be an impaired ability for vascular growth resulting from structural alteration of the microvascular network, which includes capillary rarefaction, increased arteriolar length and tortuosity. 5,6,28 -30 The basic observation underlying the hypothesis that essential hypertension is based on an impaired capacity for vascular growth is the nature of the structural alterations of microvascular beds in essential hypertension. 30 These alterations in the microvasculature even appear at very early stages of hypertension, 7 with remodeling of individual vessels and vascular networks (which may be a pathologic variant of the formation of mature networks) and certainly, evidence would suggest that abnormal angiogenesis may contribute causally to hypertension, as recently reviewed by Le Noble et al. 30 There is also the possibility that VEGF may be related to hemodynamic effects, including changes in arteriolar tone, enhancement of capillary permeability, and renal excretion of fluids. 30 
Limitations
We acknowledge that despite best efforts the mean BP reduction at 6 months was approximately 15/5 mm Hg. The ASCOT patient population are high risk hypertensives and the drugs used to treat (and sequence of add-on drugs) were protocol driven. It is, however, conceivable that with greater BP reductions we would have even seen greater changes in the measured indices. In view of the different drugs, dose regimes, and actual doses in the 223 treated subjects at baseline, it was not possible to correct for each and every individual agent, but different drug classes have been shown to influence clotting parameters differently. 31 We would also emphasize that this substudy essentially looks at the impact of a "package of care" of cardiovascular risk factor management, with BP and hypercholesterolemia treatment as appropriate, as well as combinations of different regimes, it would be difficult to dissect out the effects of individual drug classes. 31 We have also depended on plasma indices of endothelial damage/dysfunction and angiogenesis, and these may reflect more generalized (rather than localized) pathophysiologic processes. Indeed, vWf and VEGF/sFlt-1 are some of many factors associated with endothelial damage/dysfunction and angiogenesis. The statistically significant correlation between the measured indices and CVD/stroke scores (Table 7) is also rather modest, but the present analysis has the advantage of large numbers and the statistical power to assess these markers in our high risk hypertensive population. Although the correlation of these markers with risk in the setting of multiple risk factors is not very strong, it is broadly comparable to what is observed in other clinical studies.
In conclusion, we suggest that endothelial damage and dysregulated angiogenesis may contribute to the pathogenesis of cardiovascular risk in hypertension. Indices associated with both processes correlate with some of the risk factors used in the Framingham equation, but might add further information with regard to risk stratification. It is already established that high levels of vWf carry a poor prognosis. Future studies are needed to ascertain whether the reduction in VEGF and vWF levels may be related to improvements in prognosis by cardiovascular risk management programs.
